NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

uniQure N.V. (QURE) Stock Analysis

uniQure N.V. (QURE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

QURE

$22.69

−$0.02 (−0.11%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QURE with… →

QURE Key Statistics

As of Oct 21, 2026
Trading
Open
$23.05
Previous Close
$22.72
Day's Range
22.32–23.17
52-Week Range
8.73–71.50
Volume
1.12M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.06
Valuation
Market Cap
$1.57B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
84.29
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.03
Financials (FY)
Revenue (FY)
$16.10M−40.64%
Net Income (FY)
−$198.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
69.37M
1-Year Return
−64.02%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
2.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, QURE closed at $22.69, −64.02% over 1 year.

uniQure N.V. (QURE) has a market capitalization of $1.57B.

In fiscal 2025, QURE reported revenue of $16.10M.

QURE Stock Return by Calendar Year

uniQure N.V. (QURE) 10-year return: what $10,000 became

1 year
$10,000 $3,598
−64.02%
5 years
$10,000 $8,035
−19.65%
10 years
$10,000 $31,514
+215.14%

If you had invested $10,000 in uniQure N.V. (QURE) 10 years ago, at the close on October 21, 2016, it would have been worth $31,514 at the close on October 21, 2026: +215.14% in total, +12.16% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.18%
2025+35.50%
2024+160.86%
2023−70.14%
2022+9.31%
2021−42.60%
2020−49.58%
2019+148.65%
2018+47.12%
2017+249.82%
2016 (partial year)−32.12%

As of October 21, 2026.

QURE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.10M−$198.97M−1,236.0%
2024$27.12M−$239.56M−883.4%
2023$15.84M−$308.48M−1,947.1%
2022$106.48M−$126.79M−119.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.10M$14.41M−$187.83M−$198.97M−1,236.0%
2024$27.12M$8.79M−$182.18M−$239.56M−883.4%
2023$15.84M$2.22M−$282.49M−$308.48M−1,947.1%
2022$106.48M$103.14M−$144.25M−$126.79M−119.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QURE Valuation vs Biotechnology Median

Median of 608 stocks
MetricQUREBiotechnology medianvs median
P/S ratio84.2913.306.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

uniQure N.V. (QURE) is capitalised at $1.57B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 221 employees.

The 52-week range on file runs from $8.73 to $71.50. The most recent close on file for QURE is $22.69, dated October 21, 2026. That is −$0.02 (−0.11%) against the previous close. The latest close sits 159.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.10M. That is −40.64% against the prior fiscal year, when revenue was $27.12M. The same year closed with a net loss of $198.97M. Earnings per share on a trailing basis come to −4.03.

Across the 4 fiscal years on file, revenue moves from $106.48M in 2022 to $16.10M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 84.29 times revenue. On price-to-sales that is 6.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −64.02%. Measured over 10 years, that is +12.16% a year compounded. The reported beta is 1.06. Annualized volatility over the trailing 10 years is 122.86%.

Growth & Income

The record shows no dividend for QURE.

2026 is still running; the total return is −5.18% year to date. The strongest complete calendar year on file is 2017 at +249.82%; the weakest is 2023 at −70.14%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

uniQure N.V. (QURE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
uniQure N.V. QURE $1.57B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. uniQure N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Visit website →